Latest news with #Meetingof
Fibre2Fashion
5 days ago
- Business
- Fibre2Fashion
US firm Deckers Brands appoints Patrick Grismer to board of directors
Deckers Brands (NYSE: DECK), a global leader in designing, marketing, and distributing innovative footwear, apparel, and accessories, announced the nomination of Patrick J. Grismer for election to its Board of Directors (the 'Board') at the Company's 2025 Annual Meeting of Stockholders to be held on September 8, 2025 (the "Annual Meeting"). In connection with Mr. Grismer's nomination and as previously announced, Dave Powers will not stand for reelection to the Board at the Annual Meeting, retiring after more than nine years of service as a director. Mr. Grismer brings over 35 years of financial leadership experience at major global consumer companies. He currently serves on the board of directors of Krispy Kreme and recently served as chair of the board of directors of Panera Brands. Mr. Grismer previously held CFO roles at Starbucks Coffee Company, Hyatt Hotels Corporation and Yum! Brands, where he oversaw significant business transformations and value-creation initiatives, as well as executive leadership positions at The Walt Disney Company. Mr. Grismer earned a B.S. in Accounting from the University of Southern California and an M.B.A. from Northwestern University. If Mr. Grismer is elected to the Board at the Annual Meeting, he is expected to join the Audit & Risk Management Committee. Maha S. Ibrahim, a member of the Audit & Risk Management Committee, is expected to join the Corporate Responsibility, Sustainability & Governance Committee and step down as a member of the Audit & Risk Management Committee if reelected to the Board at the Annual Meeting. Deckers Brands has nominated Patrick J Grismerâ€'former CFO of Starbucks, Hyatt, and Yum! Brandsâ€'for election to its board at the September 8, 2025 Annual Meeting. Grismer would join the Audit Committee, as Dave Powers retires after nine years. The board praised Grismer's financial acumen and honoured Powers' impactful leadership and legacy. 'We are pleased to nominate Pat to our Board as we build on Deckers' growth trajectory and value creation,' said Cindy Davis, Chair of the Board . 'Pat's financial expertise, strategic vision and proven leadership at some of the world's most recognizable companies will be immediately additive to our oversight of Deckers' long-term strategy and the continued momentum of our iconic brands.' Mr. Grismer said, 'Deckers has created leading footwear brands that consumers are passionate about and truly connect with. I have been impressed by the Company's ability to continually extend its reach and deepen its relevance across categories and geographies, always meeting the moment. I am excited to join the Board and help advance the Company's strategy to deliver value.' Ms. Davis continued, 'On behalf of the Board, I want to thank Dave for his immense service to Deckers, both as a director and as our former CEO and President. Dave has played an instrumental role in shaping Deckers into the industry leader it is today, with unique products that blend technology and comfort. We are grateful for Dave's above-and-beyond dedication, and we wish him the best in his well-deserved retirement come September.' Mr. Powers commented, 'It has been deeply rewarding to be part of Deckers' journey since 2012, which has been marked by explosive growth and meaningful contributions to our communities. Deckers is a resilient organization with incredible talent and exemplary leaders, and the extraordinary innovation happening at HOKA and UGG will continue to set the Company apart. I am confident Deckers' future is bright, and I look forward to following its successes for years to come.' Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Fibre2Fashion News Desk (RM)
Business Wire
22-07-2025
- Business
- Business Wire
Know Labs Reminds its Stockholders to Vote Ahead of the Special Meeting on July 24
SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW) (' Know Labs ' or the ' Company '), a technology innovator specializing in non-invasive health monitoring solutions, today issued a reminder to its stockholders to vote ahead of the Special Meeting of Stockholders (the 'Special Meeting') to be held virtually on Thursday, July 24, 2025 at 1:30 p.m. pacific time. The methods for voting and submitting proxies are described in the previously distributed proxy materials for the Special Meeting. The Company's Board of Directors encourages any stockholders as of the record date of June 20, 2025, who have not yet voted their shares for the Special Meeting, to cast their vote 'For' each proposal, now. You may vote: over the Internet ( or by telephone (1-800-690-6903); or by following the instructions provided in the Notice received on or after July 1, 2025. Deadline to vote (if not voting at the meeting): Internet and telephone voting facilities for stockholders of record will close at 11:59 p.m., Eastern time, on July 23, 2025. You may have received your instructions to vote directly from your broker or via email from on or after July 1, 2025. This is a friendly reminder to please vote your shares as soon as possible. The board unanimously recommends stockholders vote FOR each of the Proposals. About Know Labs, Inc. Know Labs, Inc. is a public company whose common shares trade on the NYSE American Exchange under the stock symbol 'KNW.' The Company's platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market. Other products, based upon the Company's technology may not require such FDA approval. No Offer or Solicitation This communication is for informational purposes only and is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Forward-Looking Statements This release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the current intent, beliefs, expectations and assumptions of the Company, its directors or its officers regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of its control. The Company's actual results and financial condition may differ materially from those indicated in the forward-looking statements. No forward-looking statement is a guarantee of future performance. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of Bitcoin and any associated impairment charges that the Company may incur as a result of a decrease in the market price of Bitcoin below the value at which the Company's Bitcoin are carried on its balance sheet; (ii) the effect of and uncertainties related the ongoing volatility in interest rates; (iii) the Company's ability to achieve and maintain profitability in the future; (iv) the timing to consummate the proposed transaction; (v) the risk that a condition of closing of the proposed transaction may not be satisfied or that the closing of the proposed transaction might otherwise not occur; (vi) the impact of the regulatory environment on the Company's business and complexities with compliance related to such environment including changes in securities laws or other laws or regulations; (vii) changes in the accounting treatment relating to the Company's Bitcoin holdings; (viii) the Company's ability to respond to general economic conditions; (ix) the Company's ability to manage its growth effectively and its expectations regarding the development and expansion of its business; (x) the Company's ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth and (xi) other risks and uncertainties more fully in the section captioned 'Risk Factors' in the Company's most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2024, Forms 10-Q and 8-K, and other reports file with the SEC from time to time. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are only made as of this date, and the Company undertakes no duty to update such information after the date of this announcement except as required under applicable law.
Business Wire
16-07-2025
- Business
- Business Wire
The St. Joe Company to Announce Second Quarter 2025 Results and Hold Earnings Call for the Second Quarter
PANAMA CITY BEACH, Fla.--(BUSINESS WIRE)--The St. Joe Company (NYSE: JOE) will release its second quarter 2025 results after the market closes on Wednesday, July 23, 2025. An earnings release will be posted on the Investor Relations section of the Company's website at As discussed at its 2025 Annual Meeting of Shareholders, the Company will conduct an earnings call on July 24, 2025 at 3:00 p.m. Central Time; 4:00 p.m. Eastern Time to answer questions regarding the results. To join the call, please click here. Replay of the call will be available until August 20, 2025 at About The St. Joe Company The St. Joe Company is a diversified real estate development, asset management and operating company with real estate assets and operations in Northwest Florida. The Company intends to use existing assets for residential, hospitality and commercial ventures. St. Joe has significant residential and commercial land-use entitlements. The Company actively seeks higher and better uses for its real estate assets through a range of development activities. More information about the Company can be found on its website at © The St. Joe Company 2025. All Rights Reserved. 'St. Joe ®,' 'JOE ®,' the 'Taking Flight' Design ®" and 'St. Joe (and Taking Flight Design) ® ' are the registered marks of The St. Joe Company.
Business Wire
04-07-2025
- Business
- Business Wire
QT Imaging to Hold Virtual 2025 Annual Meeting of Stockholders on August 19
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced that its 2025 Annual Meeting of Stockholders will be held as a virtual meeting on Tuesday, August 19, 2025, at 1:00 p.m. EDT (10:00 a.m. PDT). Stockholders of record at the close of business on July 16, 2025 shall be entitled to vote at the 2025 Annual Meeting. Information about the virtual meeting webcast and instructions for how stockholders can participate in the 2025 Annual Meeting will be included in the definitive proxy statement to be filed with the Securities and Exchange Commission and will be available on the "Investors" section of QT Imaging's website at About QT Imaging Holdings, Inc. QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the company's website at Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as 'will,' and 'expect,' or the negative thereof or comparable terminology, and include (without limitation) statements regarding the date of its annual meeting of stockholders. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and 'bring to market' plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of QT Imaging Holding's filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
Business Wire
01-07-2025
- Business
- Business Wire
SAIF Partners Sends Letter to Sinovac Shareholders
NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., ('SAIF Partners'), the largest single investor in Sinovac Biotech Ltd. ('Sinovac' or the 'Company'), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board's empty promises to shareholders, numerous failures overseeing the Company, and certain directors' concerning patterns of reckless, unethical and illegal actions to retain control of Sinovac. The full text of the letter is as follows: Dear Fellow Sinovac Shareholders, SAIF Partners ('we' or 'us') is the largest single investor and a long-term shareholder in Sinovac Biotech Ltd. ('Sinovac' or the 'Company'). We beneficially own approximately 15% of the Company's outstanding common shares. As you are likely aware, on June 24, 2025, Sinovac's Board of Directors (the 'Board') announced its intention to pay 'up to' $138.73 per share in total dividends to shareholders – a significant increase from Sinovac's previously announced $55 per share dividend scheduled to be distributed on or about July 7, 2025. As a financial investor in Sinovac just like you, we welcome the idea of the Company distributing these significant dividends. However, we have serious doubts that the current Board will be able to deliver any further dividends to you. Don't Believe Empty Promises: Sinovac's Current Board Failed to Act Until it Was Pressured by Shareholders and Became Desperate to Win Your Votes to Retain Control of Sinovac Shareholders should not be fooled by the current Board's empty promises intended to protect the status quo and retain their positions. Sinovac's current directors – the majority of whom were not duly elected by shareholders – have offered up such large dividends only because their positions are on the line at the upcoming Special Meeting of Shareholders (the 'Special Meeting') to be held on July 8, 2025, and they are trying to buy shareholders' support. Further, the misleading dividend plan outlined by the current Board reveals its recklessness and its ignorance of the nature of Sinovac's business, the financial status of the Company, and the applicable PRC laws and regulations under which the Company operates: All of Sinovac's profits over the past several years were created by the former Board and management team. The current Board contributed nothing to the generation of the Company's profits. The previously-announced $55 per share dividend – for which the current Board is seeking to take credit – was distributed from Sinovac's Chinese subsidiaries to the Company before 2025 by the former Board and was made ready for further distribution to shareholders by the former Board and management, not the current Board. That dividend was originally withheld because of the chaos created by the lawsuit regarding the 2018 takeover of Sinovac's Board by representatives of minority shareholders 1Globe and Orbimed. The current Board only recently announced its plan to distribute the dividend once it faced public pressure from shareholders including SAIF Partners. This chaotic lawsuit – led by the belligerent 1Globe and Orbimed group – has mired Sinovac in a series of legal battles that have left shareholders unable to trade the Company's stock or receive long-overdue dividend payments. If the current Board is not removed, we believe shareholders' capital will remain trapped within the Company indefinitely. Further, under the current Board, Sinovac's independent auditor, Grant Thornton Zhitong Certified Public Accountants LLP ('Grant Thornton'), resigned on April 21, 2025, and since then the Company has operated without an auditor. Given that Grant Thornton's resignation was prompted by the current Board's governance failures, we have good reason to believe that no auditor will work for Sinovac until there is a fundamental change in the Company's governance practices. We do not believe the current Board will be able to retain a new auditor given its long-term conflict with management and other shareholders. Given these realities, it appears to us that Sinovac's current Board has thrown out a massive dividend figure purely to win your votes – without consulting the people who run the Company, and without audited financial data required to make an informed judgement regarding the Company's capacity to pay dividends. The 1Globe and Orbimed Group Have Taken Reckless, Unethical and Illegal Actions to Take Control of Sinovac Sinovac operates within the highly regulated public health sector. It is critical that the Company maintains the highest respect for laws and ethics, requiring that it has principled, ethical leaders at its helm. However, the 1Globe and Orbimed group have employed a reckless approach and have previously acted with flagrant disregard for both professional ethics and applicable laws. For instance: In or about November 2018, Sinovac directors Mr. Pengfei Li and Mr. Jianzeng Cao – both directors nominated by 1Globe and Orbimed – were prohibited by the Hong Kong High Court from purporting to act or holding themselves out as Directors of Sinovac Hong Kong or its subsidiaries. The Hong Kong High Court found that Mr. Li and Mr. Cao forged documents and illegally filed them with the Hong Kong Companies Registry in an attempt to unlawfully remove Directors of Sinovac Hong Kong, and to deceive the Hong Kong Companies Registry into believing that the Board of Sinovac Hong Kong had been reconstituted. In May of 2020, the U.S. Securities and Exchange Commission (the 'SEC') found that Dr. Chiang Li and 1Globe violated federal securities laws and regulations and imposed civil money penalties on them. Specifically, the SEC found that by the end of 2017, 1Globe, Dr. Chiang Li and Dr. Chiang Li's relatives 'together held nearly one-third of the common stock of [Sinovac] and participated in an activist plan to replace four of five incumbent directors . . . at Sinovac's 2018 annual shareholder meeting.' 1Globe and Dr. Chiang Li, however, 'failed to disclose their full beneficial ownership of Sinovac stock, inclusive of substantial shares held by related parties, and their participation in a plan, led by other investors, thereby depriving existing and potential shareholders of information necessary to make fully informed investment decisions.' Based on its findings, the SEC ordered that 1Globe and Dr. Chiang Li cease and desist from committing or causing any violations and any future violations of Sections 13(d)(1) and 13(d)(2) of the Exchange Act and Rules 13d–1 and 13d–2 thereunder. The SEC also imposed civil penalties on both 1Globe and Dr. Chiang Li, with 1Globe agreeing to pay USD $200,000 and Dr. Chiang Li agreeing to pay USD $90,000 in civil money penalties. In or about February 2024, it was reported that Shandong Sinobioway Biomedicine Co., Ltd. ('Shandong Sinobioway', a public listed company in the PRC), had received a criminal judgment from the People's Court of Zhangdian District, Zibo City, Shandong Province ('Shandong Court'), in which Mr. Pengfei Li was one of the named defendants. Mr. Pengfei Li is the CEO of 1Globe China, and it is believed he committed the criminal behaviors as part of 1Globe's scheme to take control of Sinovac and its subsidiaries. The Shandong Court found that Mr. Pengfei Li had committed the crimes of embezzlement, forging government documents and seals, and forging company seals, and sentenced him to eight years in prison and ordered that he pay a fine of RMB 780,000. In addition, the Shandong Court ruled that Hangzhou Qiangxin Biotechnology Co., Ltd., a Chinese subsidiary of 1Globe, had illegally acquired a 34% equity interest in Sinobioway Biomedicine Co., Ltd., a wholly owned subsidiary of Shandong Sinobioway and the minority shareholder of Sinovac's Beijing joint venture. Given these unscrupulous behaviors over a long period of time, we strongly doubt that the current Board will ever be able to build the internal and external support to effectively oversee Sinovac, maintain financial discipline, and pay the significant dividends it has promised to you in an effort to win your vote. A New Board is Immediately Needed to Restore Sinovac's Credibility and Maximize Shareholder Value We believe that immediate change is needed on Sinovac's Board to unlock the tremendous value embedded in the Company for all shareholders. To that end, we have nominated ten highly qualified director candidates for election to the Board at the upcoming Special Meeting who are committed to resolving Sinovac's legal disputes, retaining a new independent auditor, and taking the steps necessary to deliver value to all shareholders, including: Immediately paying out the long-scheduled USD $55 per share dividend to shareholders; Ending the six-year trading halt of Sinovac's common shares, which has left the stock at a price of $6.47 per share – reflecting only a fraction of the Company's current value; Paying shareholders further dividends based on the Company's audited financial accounts. If elected, SAIF's nominees – who include Sinovac's founder and current CEO – will bring extensive industry knowledge, management experience, and shareholder alignment to the Board, and work closely with management to bring disciplined corporate governance, proper capital allocation, strategic foresight and operational excellence to the Company. SAIF Partners urges all Sinovac shareholders to vote the GOLD Proxy Card 'FOR' the removal of the current Board and 'FOR' the election of our ten highly qualified director nominees to the Board at the Special Meeting of Shareholders. Now is Your Chance to Elect a Board that Will Act in the Best Interest of ALL Sinovac Shareholders VOTE THE GOLD PROXY CARD TODAY YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY OR HOW FEW SHARES YOU OWN! Please vote today by telephone or via the Internet by following the easy instructions on the GOLD proxy card. If you have any questions or require assistance in authorizing a proxy or voting your common shares, please contact: Sodali & Co 430 Park Avenue, 14th Floor New York, NY 10022 Call Toll-Free in North America: (800) 662-5200 Outside of North America Call Collect: (203) 658-9400 Email: SAIF@ Expand About SAIF Partners SAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices. Additional Information and Where to Find it This communication may be deemed to be solicitation material in respect of SAIF Partners' nomination of ten director nominees to Sinovac's Board. In connection with such solicitation, SAIF Partners mailed the definitive proxy statement and proxy card to shareholders of Sinovac with respect to the Special Meeting to be held in connection with the election of directors to Sinovac's Board. The definitive proxy statement mailed by SAIF Partners is also filed as Exhibit 1 to its Schedule 13D/A filed on or about June 16, 2025. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE SINOVAC SPECIAL MEETING, INCLUDING ANY DOCUMENT INCORPORATED BY REFERENCE THEREIN, CAREFULLY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE DIRECTOR NOMINEES AND THE SPECIAL MEETING AND RELATED MATTERS. Sinovac's shareholders may obtain, free of charge, the definitive version of the proxy statement, any amendments or supplements thereto, and any other relevant documents mailed by SAIF Partners in connection with the Special Meeting at
